FluCold LOR (Tablets) Instructions for Use
Marketing Authorization Holder
Canonpharma Production, CJS (Russia)
ATC Code
R02AA20 (Other antiseptics)
Active Substances
Pyridoxine (Rec.INN registered by WHO)
Lysozyme (DCF adopted for use in France)
Dosage Form
| FluCold LOR | Lozenges 20 mg+10 mg: 10 or 30 pcs. |
Dosage Form, Packaging, and Composition
Lozenges white or almost white, round, flat-cylindrical, with a bevel and a score, with a characteristic odor.
| 1 tab. | |
| Lysozyme hydrochloride | 20 mg |
| Pyridoxine hydrochloride | 10 mg |
Excipients: vanilla flavor – 0.1 mg, tragacanth gum – 10 mg, magnesium stearate – 2 mg, mannitol – 157.4 mg, sodium saccharin – 0.5 mg.
10 pcs. – blister packs – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
Clinical-Pharmacological Group
Topical antiseptic for use in ENT practice and dentistry
Pharmacotherapeutic Group
Antiseptic
Pharmacological Action
Combined antiseptic agent.
Lysozyme is an enzyme of protein nature, used as an antiseptic due to its direct effect on gram-positive and gram-negative bacteria, as well as fungi and viruses. It participates in the regulation of local nonspecific immunity.
Pyridoxine has a protective effect on the oral mucosa (has an anti-aphthous effect). It does not affect the pharmacodynamic properties of lysozyme.
Indications
Treatment of infectious and inflammatory diseases of the oral mucosa, gums, and larynx: gingivitis; stomatitis; catarrhal phenomena of the upper respiratory tract; aphthous ulcerations; herpetic lesions of the oral mucosa (as part of complex therapy); erosions of the oral mucosa of various etiologies.
ICD codes
| ICD-10 code | Indication |
| B00.2 | Herpetic gingivostomatitis and pharyngotonsillitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04.0 | Acute laryngitis |
| J06.9 | Acute upper respiratory infection, unspecified |
| J31.2 | Chronic pharyngitis |
| J35.0 | Chronic tonsillitis |
| J37.0 | Chronic laryngitis |
| K05 | Gingivitis and periodontal diseases |
| K12 | Stomatitis and related lesions |
| ICD-11 code | Indication |
| 1F00.0 | Infection of skin or mucous membranes caused by herpes simplex virus |
| 1F00.02 | Gingivostomatitis caused by herpes simplex virus |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05.0 | Acute laryngitis |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| CA09.2 | Chronic pharyngitis |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| DA01.Z | Diseases of the oral mucosa, unspecified |
| DA0B.Z | Gingival diseases, unspecified |
| DA0C.Z | Periodontal diseases, unspecified |
| DA0Z | Diseases or disorders of the orofacial complex, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Use topically in the oral cavity. Dissolve the lozenge slowly and completely in the mouth.
For adults and children over 3 years of age, administer 3 to 4 times per day.
Adhere to a minimum interval of 3-4 hours between doses.
The standard course of treatment is 8 days. Do not exceed the recommended duration of use without medical consultation.
For herpetic lesions of the oral mucosa, use only as part of a complex therapy as directed by a physician.
If symptoms persist after the 8-day course, discontinue use and seek medical advice.
Adverse Reactions
Possible allergic reactions.
Contraindications
Children under 3 years of age; hypersensitivity to the components of the combination.
Use in Pregnancy and Lactation
Can be used during pregnancy and lactation (breastfeeding).
Special Precautions
If an allergic reaction occurs, use should be discontinued.
Drug Interactions
When used concomitantly, the combination enhances the action of antibiotics, including penicillin, chloramphenicol, nitrofurantoin, enhances the effect of diuretics, and weakens the activity of levodopa.
Isoniazid, penicillamine, pyrazinamide, immunosuppressants, estrogens, and oral contraceptives may increase the need for pyridoxine (antagonistic action against pyridoxine or increased renal excretion).
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer